SG10201605196PA - Novel Inhibitor Compounds Of Phosphodiesterase Type 10A - Google Patents
Novel Inhibitor Compounds Of Phosphodiesterase Type 10AInfo
- Publication number
- SG10201605196PA SG10201605196PA SG10201605196PA SG10201605196PA SG10201605196PA SG 10201605196P A SG10201605196P A SG 10201605196PA SG 10201605196P A SG10201605196P A SG 10201605196PA SG 10201605196P A SG10201605196P A SG 10201605196PA SG 10201605196P A SG10201605196P A SG 10201605196PA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor compounds
- phosphodiesterase type
- novel inhibitor
- novel
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503040P | 2011-06-30 | 2011-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201605196PA true SG10201605196PA (en) | 2016-08-30 |
Family
ID=46456562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201605196PA SG10201605196PA (en) | 2011-06-30 | 2012-06-28 | Novel Inhibitor Compounds Of Phosphodiesterase Type 10A |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9938269B2 (en) |
| EP (1) | EP2726479A1 (en) |
| JP (1) | JP2014518237A (en) |
| KR (1) | KR20140050028A (en) |
| CN (1) | CN103958504B (en) |
| AR (1) | AR086817A1 (en) |
| AU (1) | AU2012277802A1 (en) |
| BR (1) | BR112013033696A2 (en) |
| CA (1) | CA2839655A1 (en) |
| CL (1) | CL2013003731A1 (en) |
| CO (1) | CO6870032A2 (en) |
| CR (1) | CR20140023A (en) |
| DO (1) | DOP2013000315A (en) |
| EC (1) | ECSP14013188A (en) |
| GT (1) | GT201300324A (en) |
| MX (1) | MX2013015390A (en) |
| NZ (1) | NZ618930A (en) |
| PE (1) | PE20141308A1 (en) |
| RU (1) | RU2014102962A (en) |
| SG (1) | SG10201605196PA (en) |
| TW (1) | TW201311662A (en) |
| UY (1) | UY34177A (en) |
| WO (1) | WO2013000994A1 (en) |
| ZA (1) | ZA201309561B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2632461A4 (en) * | 2010-10-29 | 2014-04-02 | Merck Sharp & Dohme | Isoindolinone pde10 inhibitors |
| RU2646754C2 (en) * | 2012-04-25 | 2018-03-07 | Раквалиа Фарма Инк. | Pyrrolopyridinone derivatives as ttx-s blockers |
| DE102012016908A1 (en) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris (hetero) aryl-pyrazoles and their use |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| EP2970258B1 (en) | 2013-03-14 | 2018-04-18 | AbbVie Deutschland GmbH & Co KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| GB201322334D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | Maleimide derivatives as modulators of WNT pathway |
| EP3099690B1 (en) | 2014-01-31 | 2019-08-28 | F.Hoffmann-La Roche Ag | (hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders |
| SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
| CA2943882A1 (en) * | 2014-05-22 | 2015-11-26 | F. Hoffmann-La Roche Ag | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives |
| TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
| PT3207043T (en) | 2014-10-14 | 2019-03-25 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridine inhibitors of ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| AR104291A1 (en) | 2015-04-17 | 2017-07-12 | Abbvie Inc | TRICYCLIC MODULATORS OF TNF SIGNALING |
| WO2016168638A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| ES2856931T3 (en) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | ROR-gamma modulators |
| AU2016341520C1 (en) | 2015-10-21 | 2021-07-22 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| SG11201803234TA (en) | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| US10112955B2 (en) * | 2015-10-29 | 2018-10-30 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| EP3377482B1 (en) | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (en) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | Modulators of ror-gamma |
| CR20180413A (en) | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | INHIBITORS OF PROTEIN QUINASA 1 THAT INTERACT WITH THE RECEIVER |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3552017B1 (en) | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
| WO2018152117A1 (en) | 2017-02-14 | 2018-08-23 | Effector Therapeutics, Inc. | Piperidine-substituted mnk inhibitors and methods related thereto |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| US11584744B2 (en) * | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
| AR112461A1 (en) | 2017-07-24 | 2019-10-30 | Vitae Pharmaceuticals Inc | PROCESSES FOR THE PRODUCTION OF SALTS AND CRYSTAL FORMS OF RORg INHIBITORS |
| KR20200094734A (en) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Heterocyclic compounds as PAD inhibitors |
| DK3697785T3 (en) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| CA3083374A1 (en) | 2017-11-24 | 2019-05-31 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
| MX2020009372A (en) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones. |
| AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
| JP2022501335A (en) | 2018-09-28 | 2022-01-06 | 武田薬品工業株式会社 | Balipodect for the treatment or prevention of autism spectrum disorders |
| AU2019366947A1 (en) | 2018-10-24 | 2021-06-03 | Effector Therapeutics, Inc. | Crystalline forms of Mnk inhibitors |
| WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
| CN109608444B (en) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | Isoindolinone-containing ERK inhibitor and preparation method and application thereof |
| CN114258392A (en) * | 2019-08-21 | 2022-03-29 | 卡尔维斯塔制药有限公司 | Enzyme inhibitors |
| US11005924B1 (en) | 2020-04-01 | 2021-05-11 | Netapp, Inc. | Disparity of quality of service (QoS) settings of volumes across a cluster |
| US11140219B1 (en) | 2020-04-07 | 2021-10-05 | Netapp, Inc. | Quality of service (QoS) setting recommendations for volumes across a cluster |
| US20240076291A1 (en) * | 2020-11-24 | 2024-03-07 | Merck Sharp & Dohme Llc | Modified isoindolinones as glucosylceramide synthase inhibitors |
| US11693563B2 (en) * | 2021-04-22 | 2023-07-04 | Netapp, Inc. | Automated tuning of a quality of service setting for a distributed storage system based on internal monitoring |
| CN114805052A (en) * | 2022-06-07 | 2022-07-29 | 华衍化学(上海)有限公司 | Method for synthesizing p-vinylbenzoic acid |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1560726A (en) * | 1976-04-28 | 1980-02-06 | Beecham Group Ltd | Isothiazolo-pyridines |
| JPH02268162A (en) * | 1989-04-10 | 1990-11-01 | Fujisawa Pharmaceut Co Ltd | Diphenylpyridine derivative |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| DE10134482A1 (en) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituted isoindoles and their use |
| US20030166476A1 (en) | 2002-01-31 | 2003-09-04 | Winemiller Mark D. | Lubricating oil compositions with improved friction properties |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US20060160814A1 (en) | 2004-09-03 | 2006-07-20 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| CA2588812A1 (en) | 2004-11-29 | 2006-06-01 | Warner-Lambert Company Llc | Therapeutic pyrazolo[3,4-b] pyridines and indazoles |
| US7521557B2 (en) * | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
| CN101228164A (en) * | 2005-05-20 | 2008-07-23 | 布里斯托尔-迈尔斯·斯奎布公司 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
| US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (en) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| JP2009524637A (en) | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | Aminophthalazine derivative compounds |
| MX2008010671A (en) | 2006-02-21 | 2008-10-01 | Amgen Inc | Cinnoline derivatives as phosphodiesterase 10 inhibitors. |
| EP1991530A1 (en) | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| EP1996587A1 (en) | 2006-02-23 | 2008-12-03 | Pfizer Products Incorporated | Substituted quinazolines as pde10 inhibitors |
| AU2007221049A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| EP1996574A1 (en) | 2006-03-08 | 2008-12-03 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200806625A (en) | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| JP2009542732A (en) | 2006-07-10 | 2009-12-03 | ハー・ルンドベック・アクチエゼルスカベット | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) of 6,7-dialkoxyquinazoline, 6,7-dialkoxyphthalazine and 6,7-dialkoxyisoquinoline and ( 2-Aryl-thiomorpholin-4-yl) derivatives |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| US20090143392A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| AU2008329072A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10 |
| CN101918408A (en) | 2007-11-30 | 2010-12-15 | 惠氏有限责任公司 | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| WO2010077686A1 (en) | 2008-12-08 | 2010-07-08 | Sirtris Pharmaceuticals, Inc. | Isoindolinone and related analogs as sirtuin modulators |
| WO2010138585A1 (en) | 2009-05-29 | 2010-12-02 | Merck Sharp & Dohme Corp. | Pyrimidinones as pde10 inhibitors |
| TWI481607B (en) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 2-arylimidazole derivatives as pde10a enzyme inhibitors |
| TWI485151B (en) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | Heteroaromatic phenylimidazole derivatives as pde 10a enzyme inhibitors |
| EP2632461A4 (en) * | 2010-10-29 | 2014-04-02 | Merck Sharp & Dohme | Isoindolinone pde10 inhibitors |
| SG190802A1 (en) * | 2010-12-20 | 2013-07-31 | Pfizer | Novel fused pyridine compounds as casein kinase inhibitors |
-
2012
- 2012-06-27 US US13/534,127 patent/US9938269B2/en active Active
- 2012-06-28 NZ NZ618930A patent/NZ618930A/en not_active IP Right Cessation
- 2012-06-28 SG SG10201605196PA patent/SG10201605196PA/en unknown
- 2012-06-28 WO PCT/EP2012/062544 patent/WO2013000994A1/en active Application Filing
- 2012-06-28 AU AU2012277802A patent/AU2012277802A1/en not_active Abandoned
- 2012-06-28 KR KR1020147002761A patent/KR20140050028A/en not_active Application Discontinuation
- 2012-06-28 JP JP2014517695A patent/JP2014518237A/en active Pending
- 2012-06-28 EP EP12731416.9A patent/EP2726479A1/en active Pending
- 2012-06-28 CA CA2839655A patent/CA2839655A1/en not_active Abandoned
- 2012-06-28 MX MX2013015390A patent/MX2013015390A/en unknown
- 2012-06-28 BR BR112013033696A patent/BR112013033696A2/en not_active IP Right Cessation
- 2012-06-28 PE PE2013002907A patent/PE20141308A1/en not_active Application Discontinuation
- 2012-06-28 CN CN201280042318.5A patent/CN103958504B/en not_active Expired - Fee Related
- 2012-06-28 RU RU2014102962/04A patent/RU2014102962A/en not_active Application Discontinuation
- 2012-06-29 TW TW101123611A patent/TW201311662A/en unknown
- 2012-06-29 UY UY0001034177A patent/UY34177A/en not_active Application Discontinuation
- 2012-06-29 AR ARP120102358A patent/AR086817A1/en unknown
-
2013
- 2013-12-18 ZA ZA2013/09561A patent/ZA201309561B/en unknown
- 2013-12-26 GT GT201300324A patent/GT201300324A/en unknown
- 2013-12-26 CL CL2013003731A patent/CL2013003731A1/en unknown
- 2013-12-27 DO DO2013000315A patent/DOP2013000315A/en unknown
-
2014
- 2014-01-16 CR CR20140023A patent/CR20140023A/en unknown
- 2014-01-27 CO CO14015863A patent/CO6870032A2/en unknown
- 2014-01-30 EC ECSP14013188 patent/ECSP14013188A/en unknown
-
2018
- 2018-04-09 US US15/948,299 patent/US20180222905A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201309561B (en) | 2014-08-27 |
| AU2012277802A8 (en) | 2014-03-06 |
| AU2012277802A1 (en) | 2014-01-09 |
| CO6870032A2 (en) | 2014-02-20 |
| BR112013033696A2 (en) | 2016-08-30 |
| US20130005705A1 (en) | 2013-01-03 |
| RU2014102962A (en) | 2015-08-10 |
| WO2013000994A1 (en) | 2013-01-03 |
| CN103958504A (en) | 2014-07-30 |
| PE20141308A1 (en) | 2014-10-26 |
| ECSP14013188A (en) | 2014-12-30 |
| UY34177A (en) | 2013-01-31 |
| TW201311662A (en) | 2013-03-16 |
| KR20140050028A (en) | 2014-04-28 |
| CL2013003731A1 (en) | 2014-10-10 |
| MX2013015390A (en) | 2014-07-14 |
| CN103958504B (en) | 2016-10-12 |
| US9938269B2 (en) | 2018-04-10 |
| NZ618930A (en) | 2015-05-29 |
| JP2014518237A (en) | 2014-07-28 |
| CA2839655A1 (en) | 2013-01-03 |
| DOP2013000315A (en) | 2014-04-15 |
| GT201300324A (en) | 2014-09-26 |
| CR20140023A (en) | 2014-08-21 |
| US20180222905A1 (en) | 2018-08-09 |
| AR086817A1 (en) | 2014-01-22 |
| EP2726479A1 (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201605196PA (en) | Novel Inhibitor Compounds Of Phosphodiesterase Type 10A | |
| HK1201519A1 (en) | Inhibitors of phosphodiesterase type 10a 10a | |
| IL245309B (en) | Tricyclic heterocyclic compounds as jak inhibitors | |
| HRP20180139T1 (en) | Substituted pyridopyrazines as novel syk inhibitors | |
| HK1199203A1 (en) | Kinase inhibitor polymorphs | |
| EP2721023A4 (en) | Metalloenzyme inhibitor compounds | |
| EP2723731A4 (en) | Metalloenzyme inhibitor compounds | |
| EP2721021A4 (en) | Metalloenzyme inhibitor compounds | |
| IL231352A0 (en) | New enzyme inhibitor compounds | |
| IL231353A0 (en) | New enzyme inhibitor compounds | |
| HK1201271A1 (en) | Kinase inhibitor polymorphs | |
| EP2758387A4 (en) | Pyridine compounds as inhibitors of kinase | |
| HK1206728A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| SG10201405403QA (en) | Novel salts of dpp-iv inhibitor | |
| EP2751117A4 (en) | Metalloenzyme inhibitor compounds | |
| GB201113689D0 (en) | Novel PDE4 inhibitors | |
| HK1211581A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| HK1211284A1 (en) | Inhibitor compounds of phosphodiesterase type 10a 10a | |
| AP2013007101A0 (en) | Novel salts of DPP-IV inhibitor |